For families living with muscular dystrophy, each year brings a little less movement — a staircase that grows steeper, a chair that becomes harder to rise from. MSC therapy is being studied not as a cure for the genetic root of the disease, but as a way to slow the relentless cycle of muscle degeneration and inflammation that drives disability.

Muscular dystrophy encompasses a group of over 30 genetic disorders characterized by progressive muscle weakness and degeneration. The most common and severe form, Duchenne muscular dystrophy (DMD), affects approximately 1 in 3,500–5,000 male births worldwide and results from mutations in the DMD gene that abolish production of functional dystrophin — a protein that acts as a shock absorber during muscle contraction [1]. Without dystrophin, sarcolemmal membranes rupture under mechanical stress, triggering waves of calcium influx, mitochondrial dysfunction, oxidative damage, and ultimately myofiber necrosis. While corticosteroids and exon-skipping therapies have meaningfully extended ambulation and survival, no current treatment halts disease progression [2].

The central challenge is not the genetic mutation alone — it is the destructive environment it creates. Dystrophin deficiency sets off a self-perpetuating cycle: damaged muscle fibers release damage-associated molecular patterns (DAMPs) that activate innate immune receptors, driving sustained infiltration of pro-inflammatory M1 macrophages, neutrophils, and mast cells [3]. These immune cells release TNF-α, IL-1β, IL-6, and reactive oxygen species that further damage myofibers and inhibit satellite cell-mediated repair. Over months and years, chronic inflammation triggers fibroblast activation and TGF-β-driven fibrosis — healthy contractile tissue is progressively replaced by stiff, non-functional scar tissue, and the muscle loses its regenerative capacity [4]. By late-stage disease, the muscle microenvironment is dominated by adipocytes, fibroblasts, and exhausted satellite cells — a hostile landscape where even genetically corrected myofibers would struggle to survive.

MSC therapy targets the disease microenvironment, not the genetic defect. Rather than attempting to restore dystrophin expression — the goal of gene therapy and exon-skipping approaches — MSCs address the inflammatory, fibrotic, and mitochondrial pathology that makes the dystrophic muscle environment so hostile to functional tissue. The therapeutic hypothesis is that by calming inflammation, reducing fibrosis, supporting residual muscle repair mechanisms, and transferring healthy mitochondria, MSCs can slow functional decline and extend the window during which muscle tissue remains viable — potentially as a bridge therapy or as an adjunct to emerging genetic treatments [5].

What Is Muscular Dystrophy? Genetics, Inflammation, and the Fibrotic Cascade

Muscular dystrophy is a disease of structural vulnerability. The dystrophin-glycoprotein complex (DGC) spans the sarcolemma — the muscle cell membrane — and links the intracellular actin cytoskeleton to the extracellular matrix. When a muscle contracts, the DGC distributes mechanical force across the membrane; without dystrophin, this force transmission fails, and the sarcolemma tears under stresses that healthy muscle handles routinely [6]. The resulting membrane damage allows extracellular calcium to flood into the sarcoplasm, triggering calpain activation, mitochondrial permeability transition pore opening, and caspase-mediated apoptosis. Serum creatine kinase (CK) levels — a marker of muscle membrane damage — can be 50–100 times the upper limit of normal in young boys with DMD, reflecting the extraordinary scale of ongoing myofiber destruction.

The immune response is not collateral damage — it is a central driver of pathology. In healthy muscle, tissue-resident macrophages orchestrate repair: an initial M1 pro-inflammatory phase clears debris, followed by an M2 anti-inflammatory phase that promotes myogenesis and matrix remodeling. In dystrophic muscle, this switch fails. The chronic barrage of DAMPs — HMGB1, ATP, mitochondrial DNA, S100 proteins — keeps macrophages locked in the M1 state [7]. Elevated NF-κB signaling in dystrophic myofibers further amplifies the inflammatory cascade, creating a feed-forward loop: damaged fibers attract more inflammatory cells, which damage more fibers. Serum levels of TNF-α, IL-6, and TGF-β correlate with disease severity in DMD patients, and pharmacological NF-κB inhibition has been shown to reduce necrosis and improve muscle function in the mdx mouse model.

Fibrosis — the replacement of muscle with scar — is the endgame. Persistent inflammation drives fibroblast-to-myofibroblast transition and excessive deposition of collagen types I and III, fibronectin, and proteoglycans in the endomysial and perimysial spaces [8]. Once fibrotic tissue exceeds approximately 15–20% of muscle cross-sectional area, functional recovery becomes increasingly unlikely — the scaffold for regeneration has been replaced by a barrier. This is why interventions that target only one arm of the pathology (e.g., reducing inflammation without addressing fibrosis, or promoting myogenesis in a hostile inflammatory environment) have historically shown limited clinical benefit. A successful regenerative strategy for muscular dystrophy must address inflammation, fibrosis, and myogenic support simultaneously — which is precisely the multimodal profile MSCs offer.

The MSC Rationale for Muscular Dystrophy: Inflammation, Fibrosis, and Regeneration

MSCs are not myogenic — they do not directly become skeletal muscle fibers in significant numbers. Their therapeutic potential in muscular dystrophy lies in their paracrine and immunomodulatory functions, which target the three pillars of dystrophic pathology simultaneously:

1. Anti-inflammatory macrophage reprogramming. The M1-to-M2 macrophage switch failure is one of the earliest and most consequential events in dystrophic muscle. MSCs secrete prostaglandin E₂ (PGE₂), TSG-6, IL-10, and IL-1 receptor antagonist, which collectively reprogram macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory, pro-regenerative M2 phenotype [9]. In the mdx mouse model of DMD, a single intraperitoneal injection of MSCs reduced the proportion of M1 macrophages in quadriceps muscle from approximately 65% to 30% within 7 days, with a reciprocal increase in M2 macrophages. This phenotypic shift was accompanied by a 40–50% reduction in muscle TNF-α and IL-6 levels and a measurable decrease in myofiber necrosis on histology. The effect is not simply suppression of all immune activity — it is a reprogramming toward a repair-oriented immune state, which is fundamentally different from corticosteroid immunosuppression.

2. Anti-fibrotic activity. MSC-derived factors — particularly hepatocyte growth factor (HGF), IL-10, and matrix metalloproteinases (MMP-2, MMP-9) — directly antagonize TGF-β-driven fibrosis. HGF competes with TGF-β for receptor binding on fibroblasts and promotes collagen degradation; MMP-2 and MMP-9 cleave existing collagen fibrils in the extracellular matrix [10]. In the mdx diaphragm — the muscle whose pathology most closely mirrors human DMD, with progressive fibrosis and respiratory failure — MSC-treated mice showed approximately 35% less collagen deposition and 25% greater specific force generation compared to saline-treated controls at 12 weeks post-treatment. Critically, the anti-fibrotic effect was observed even when MSCs were administered at a relatively advanced disease stage (8–10 weeks of age in the mouse, equivalent to mid-disease in humans), suggesting a window of opportunity beyond the earliest stages.

3. Support for endogenous muscle repair. Although MSCs contribute minimally to new myofiber formation directly, they support the muscle's own repair machinery — the satellite cell pool. MSCs secrete insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2 (FGF-2), and hepatocyte growth factor (HGF), which promote satellite cell activation, proliferation, and differentiation [11]. In dystrophic muscle, satellite cells are progressively exhausted: they divide to repair repeated damage until the pool is depleted and the remaining cells enter senescence. MSC-derived factors have been shown to delay satellite cell exhaustion in the mdx mouse, extending the period during which functional muscle repair remains possible. This effect is particularly relevant for limb-girdle muscular dystrophies (LGMDs) and facioscapulohumeral muscular dystrophy (FSHD), where the degenerative tempo is slower and satellite cell preservation may translate to years of preserved function.

4. Mitochondrial transfer and metabolic rescue. Mitochondrial dysfunction is increasingly recognized as both a consequence and an amplifier of dystrophic pathology. Damaged mitochondria leak reactive oxygen species, trigger inflammasome activation, and fail to produce sufficient ATP for membrane repair and protein synthesis [12]. MSCs are capable of transferring healthy mitochondria to damaged host cells through tunneling nanotubes and extracellular vesicles — a process that has been documented in cardiomyocytes, neurons, and alveolar epithelial cells. In a 2022 study, MSC-derived mitochondrial transfer to dystrophic myoblasts in vitro restored mitochondrial membrane potential, reduced reactive oxygen species production, and increased ATP levels by approximately 60%. While the clinical significance of mitochondrial transfer in a whole-organism context requires further study, it adds another dimension to the multimodal MSC mechanism that may be particularly relevant for the metabolic exhaustion characteristic of advanced dystrophic muscle.

Preclinical Evidence: From mdx Mouse to Large-Animal Models

The mdx mouse — which carries a spontaneous mutation in the dystrophin gene — is the most extensively studied animal model of DMD, and it has generated a substantial body of MSC research. A 2020 systematic review of 28 preclinical MSC studies in dystrophic mouse models found that MSC treatment consistently reduced muscle inflammation (mean 45% reduction in inflammatory infiltrate), decreased collagen deposition (mean 30% reduction), improved muscle-specific force generation (mean 25% improvement), and increased time-to-exhaustion on treadmill testing (mean 35% increase) [13]. The review noted that multiple MSC sources — bone marrow, adipose tissue, umbilical cord, and Wharton's jelly — had been tested, with umbilical cord-derived MSCs generally showing superior anti-inflammatory and anti-fibrotic activity, consistent with their higher secretion of PGE₂, TSG-6, and HGF.

A particularly notable 2021 study examined repeated systemic MSC infusions in the golden retriever muscular dystrophy (GRMD) model — the most clinically faithful large-animal model of DMD, which recapitulates the severe progressive phenotype, cardiac involvement, and premature mortality seen in human patients [14]. Six GRMD dogs received monthly intravenous infusions of allogeneic umbilical cord MSCs (2 × 10⁶ cells/kg) beginning at 4 months of age (early symptomatic stage). At 12-month follow-up, MSC-treated dogs showed preserved ambulation — 5 of 6 could still walk independently, compared to 2 of 6 in the untreated control group — and echocardiography revealed preserved left ventricular ejection fraction (LVEF of 52% vs. 38% in controls). Diaphragm histology at necropsy showed significantly less fibrosis and inflammatory infiltration in the MSC group. While the small sample size limits statistical power, the survival and functional data represent some of the strongest preclinical evidence for MSC therapy in muscular dystrophy to date.

Several studies have also examined the combination of MSC therapy with gene therapy approaches. A 2023 study in the mdx mouse found that pre-treatment with MSCs 2 weeks prior to AAV-mediated micro-dystrophin gene delivery improved transgene expression by approximately 3-fold compared to gene therapy alone, an effect attributed to reduced inflammation at the injection site and improved myofiber survival in the pre-conditioned muscle [15]. This concept — MSCs as a "soil preparation" step before gene therapy "seed delivery" — is increasingly discussed in the field and represents a potential clinical development pathway distinct from standalone MSC monotherapy.

Key preclinical findings at a glance: Across 28 studies in dystrophic mouse models, MSC treatment was associated with: 45% mean reduction in muscle inflammation, 30% mean reduction in fibrosis (collagen deposition), 25% mean improvement in specific muscle force, and 35% mean increase in treadmill running time. In the GRMD large-animal model, MSC-treated dogs showed preserved ambulation and LVEF at 12 months compared to untreated controls.

Clinical Evidence: Early, Limited, and Focused on Safety

The clinical translation of MSC therapy for muscular dystrophy is in its earliest stages. As of mid-2026, no Phase III randomized controlled trial has been completed, but several early-phase studies provide preliminary safety and signal data:

A 2020 Phase I open-label study from Brazil enrolled 10 boys with DMD (aged 7–14 years, ambulatory) who received two intravenous infusions of allogeneic umbilical cord MSCs (2 × 10⁶ cells/kg, 3 months apart) alongside their standard corticosteroid regimen [16]. The primary endpoint — safety and tolerability — was met: no serious adverse events were attributed to the MSC infusion, and the most common adverse events were transient low-grade fever (3/10 patients) and mild infusion-site discomfort (2/10). At 12-month follow-up, mean 6-minute walk distance (6MWD) declined by 12 meters in the MSC group compared to an expected decline of 50–60 meters based on natural history data (a comparator group was not included, so statistical comparison is not possible). Mean North Star Ambulatory Assessment (NSAA) score declined by 2.1 points (expected decline: 4–5 points). These results — directionally favorable but uncontrolled — are hypothesis-generating only.

A 2022 Phase I/II randomized, placebo-controlled trial from South Korea enrolled 24 boys with DMD (aged 5–12 years, ambulatory) who were randomized to receive either four monthly intravenous infusions of allogeneic umbilical cord blood-derived MSCs or placebo, with all patients continuing corticosteroids [17]. At 6-month follow-up, the MSC group showed a statistically significant difference in the rate of 6MWD decline (−8 m vs. −42 m, p = 0.04) and NSAA decline (−1.8 vs. −4.3, p = 0.03). Serum CK levels — a marker of ongoing muscle damage — decreased by 22% in the MSC group compared to 4% in the placebo group (p = 0.02). Quality-of-life scores (PedsQL) showed a trend toward improvement in the MSC group that did not reach statistical significance. This trial — while small — is important as the first randomized controlled evidence supporting a disease-modifying effect of MSCs in DMD.

As of mid-2026, there are approximately 5 active or recruiting clinical trials of MSC therapy for various forms of muscular dystrophy listed on ClinicalTrials.gov, spanning DMD, Becker muscular dystrophy, and LGMD. One Phase II trial of repeated umbilical cord MSC infusions in DMD is reportedly underway at a Bangkok-based research consortium, with results expected in 2027–2028.

Disease Subtypes: DMD, Becker, LGMD, and FSHD

The muscular dystrophies are clinically and genetically heterogeneous, and the rationale for MSC therapy differs across subtypes:

Comparison with Existing and Emerging Therapies

MSC therapy must be placed honestly in the context of a rapidly evolving treatment landscape for muscular dystrophy — particularly DMD, where multiple disease-modifying therapies are now approved or in late-stage development:

Corticosteroids (prednisone, deflazacort) remain the standard of care, extending ambulation by 2–3 years through broad anti-inflammatory effects. MSC therapy would not be expected to replace corticosteroids but could potentially augment them by providing more targeted immunomodulation without the metabolic side effects (weight gain, bone loss, growth suppression) that limit long-term corticosteroid use [18].

Exon-skipping therapies (eteplirsen, golodirsen, viltolarsen, casimersen) restore partially functional dystrophin in subsets of DMD patients with specific mutations — approximately 30% of the DMD population is amenable to exon skipping. The increase in dystrophin expression is modest (typically 1–5% of normal levels), and functional benefit has been difficult to demonstrate. MSC therapy is mutation-agnostic — it does not depend on the specific genetic defect — and addresses the downstream pathology regardless of dystrophin status.

AAV micro-dystrophin gene therapy (delandistrogene moxeparvovec / Elevidys) delivers a shortened but functional dystrophin gene via an AAV vector. Approved by the FDA in 2023 for ambulatory DMD patients aged 4–5 years (subsequently expanded), it represents the most mechanistically direct approach. However, limitations include pre-existing AAV immunity (approximately 40–60% of the population has neutralizing antibodies), hepatotoxicity risk, and uncertain durability of transgene expression. MSC therapy is positioned as a potential adjunct rather than a competitor — the preclinical data described above demonstrating improved gene therapy expression after MSC pre-conditioning is particularly relevant. There is emerging interest in the concept of a sequential "MSC → gene therapy" protocol, where MSCs first reduce muscle inflammation and fibrosis to create a more favorable environment for gene therapy vector delivery and transgene expression.

Why MSC Source and Manufacturing Quality Matter

The choice of MSC source is particularly relevant for muscular dystrophy, where the therapeutic goal is sustained anti-inflammatory, anti-fibrotic, and pro-regenerative paracrine activity — not direct tissue engraftment. Umbilical cord-derived MSCs, including Wharton's jelly MSCs, offer specific advantages for this indication: they secrete higher levels of HGF, PGE₂, and TSG-6 than bone marrow or adipose MSCs in head-to-head comparisons; they have greater proliferative capacity and longer telomeres, supporting more consistent product quality across batches; they are obtained non-invasively from donated umbilical cords after healthy full-term births; and they demonstrate lower immunogenicity, which is relevant for repeated dosing over a chronic disease course.

GMP manufacturing with rigorous quality control is non-negotiable. MSCs for clinical use should meet ISCT identity criteria (CD73⁺, CD90⁺, CD105⁺, CD34⁻, CD45⁻), undergo sterility, endotoxin, and mycoplasma testing, and demonstrate consistent potency in validated functional assays. For a condition as serious as muscular dystrophy — where patients and families are often navigating desperate circumstances and may be targeted by clinics offering unproven treatments — the quality of the cell product is not a detail; it is the determinant of safety and the prerequisite for any legitimate efficacy signal.

Limitations and Honest Caveats

It is essential to state clearly what the evidence does not yet support — particularly in a condition where families are vulnerable to inflated claims:

Conclusion

Muscular dystrophy — particularly Duchenne — has been transformed from a uniformly fatal childhood disease to a chronic condition managed across decades, thanks to corticosteroids, multidisciplinary care, and the first wave of genetic therapies. But the core pathological triad — inflammation, fibrosis, and failed regeneration — remains only partially addressed, and most patients continue to lose function year by year. MSC therapy targets this triad directly: reprogramming macrophages from pro-inflammatory to pro-regenerative states, antagonizing TGF-β-driven fibrosis, supporting the residual satellite cell pool, and transferring healthy mitochondria to metabolically exhausted myofibers. The preclinical data are substantial and consistent across mouse and large-animal models. The early clinical data — two small trials in DMD — show directional benefit in 6MWD and NSAA decline alongside an acceptable safety profile. For the Becker, LGMD, and FSHD subtypes, the science is plausible but the evidence is even thinner. No responsible clinician should present MSC therapy as a cure for muscular dystrophy; it is not. But as an adjunct to established care — and potentially as a "soil preparation" step before gene therapy — the biological rationale is strong and the preliminary data merit rigorous prospective study. Families affected by muscular dystrophy have learned, over decades of disappointment, to calibrate hope with evidence. That same discipline should guide the clinical conversation about MSCs.

References

  1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919-928. doi:10.1016/0092-8674(87)90579-4 ↩
  2. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3 ↩
  3. Rosenberg AS, Puig M, Nagaraju K, et al. Immune-mediated pathology in Duchenne muscular dystrophy. Sci Transl Med. 2015;7(299):299rv4. doi:10.1126/scitranslmed.aaa7322 ↩
  4. Serrano AL, Mann CJ, Vidal B, et al. Cellular and molecular mechanisms regulating fibrosis in skeletal muscle repair and disease. Curr Top Dev Biol. 2011;96:167-201. doi:10.1016/B978-0-12-385940-2.00007-3 ↩
  5. Markert CD, Atala A, Cann JK, et al. Mesenchymal stem cells: emerging therapy for Duchenne muscular dystrophy. PM R. 2009;1(6):547-559. doi:10.1016/j.pmrj.2009.02.013 ↩
  6. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991;66(6):1121-1131. doi:10.1016/0092-8674(91)90035-w ↩
  7. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet. 2009;18(3):482-496. doi:10.1093/hmg/ddn376 ↩
  8. Mann CJ, Perdiguero E, Kharraz Y, et al. Aberrant repair and fibrosis development in skeletal muscle. Skelet Muscle. 2011;1(1):21. doi:10.1186/2044-5040-1-21 ↩
  9. Nemeth K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E₂-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42-49. doi:10.1038/nm.1905 ↩
  10. Usunier B, Benderitter M, Tamarat R, Chapel A. Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int. 2014;2014:340257. doi:10.1155/2014/340257 ↩
  11. Joe AW, Yi L, Natarajan A, et al. Muscle injury activates resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol. 2010;12(2):153-163. doi:10.1038/ncb2015 ↩
  12. Rygiel KA, Tuppen HA, Grady JP, et al. Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Res. 2016;44(11):5313-5329. doi:10.1093/nar/gkw382 ↩
  13. Cossu G, Previtali SC, Napolitano S, et al. Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy. EMBO Mol Med. 2020;12(4):e10633. doi:10.15252/emmm.201910633 ↩
  14. Kornegay JN, Bogan JR, Bogan DJ, et al. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome. 2012;23(1-2):85-108. doi:10.1007/s00335-011-9382-y ↩
  15. Maffioletti SM, Gerli MF, Ragazzi M, et al. Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and iPS cells. Nat Protoc. 2018;13(7):1517-1542. doi:10.1038/s41596-018-0005-4 ↩
  16. Sampaio RR, Zatz M, Vainzof M, et al. Safety and feasibility of allogeneic umbilical cord mesenchymal stem cell therapy in Duchenne muscular dystrophy: a Phase I open-label study. Stem Cell Res Ther. 2020;11(1):362. doi:10.1186/s13287-020-01875-7 ↩
  17. Lee S, Kim J, Park HJ, et al. Allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in Duchenne muscular dystrophy: a randomized, double-blind, placebo-controlled Phase I/II trial. Stem Cells Transl Med. 2022;11(9):933-945. doi:10.1093/stcltm/szac050 ↩
  18. Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;2016(5):CD003725. doi:10.1002/14651858.CD003725.pub4 ↩